We are live on ! Find out more
SBBP

Strongbridge Biopharma plc.
SBBP

Delisted

SBBP was delisted on the 5th of October, 2021.

58 hedge funds and large institutions have $87.2M invested in Strongbridge Biopharma plc. in 2019 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 19 increasing their positions, 17 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more call options, than puts

Call options by funds: $8K | Put options by funds: $2K

58% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 12

14% more funds holding

Funds holding: 5158 (+7)

12% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 17

36% less capital invested

Capital invested by funds: $135M → $87.2M (-$48M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
58
Holders Change
+7
Holders Change %
+13.73%
% of All Funds
1.26%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
19
Increased
19
Reduced
17
Closed
12
Calls
$8K
Puts
$2K
Net Calls
+$6K
Net Calls Change
+$32K

SBBP Hedge Fund Activity: Q2 2019 in Review

58 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q2 2019, worth a combined $87.2M — down 36% from $135M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new SBBP positions and 12 closed out — a net gain of 7 holders — while 19 added to existing stakes and 17 trimmed.

The largest buyer was BlackRock, adding an estimated $6.24M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $4.74M sold.

  • 58 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q2 2019, up from 51 in Q1 2019.
  • Funds reported $87.2M of Strongbridge Biopharma plc. stock for Q2 2019, down 36% quarter-over-quarter.
  • 19 funds opened new Strongbridge Biopharma plc. positions in Q2 2019 and 12 closed out, a net change of +7 holders.
  • The largest Strongbridge Biopharma plc. buyer in Q2 2019 was BlackRock, an estimated $6.24M added.
  • The largest Strongbridge Biopharma plc. seller in Q2 2019 was Sphera Funds Management, an estimated $4.74M sold.

Based on aggregated 13F filings for Q2 2019.